Genomic Health, Inc. (GHDX)
(Delayed Data from NSDQ)
$67.55 USD
+1.67 (2.53%)
Updated May 3, 2019 04:00 PM ET
After-Market: $67.63 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$67.55 USD
+1.67 (2.53%)
Updated May 3, 2019 04:00 PM ET
After-Market: $67.63 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Abiomed (ABMD) to Replace Wyndham in the S&P 500 Benchmark
by Zacks Equity Research
Abiomed (ABMD) to join the S&P 500 Global Industry Classification Standard Health Care Supplies Sub-Industry index.
Intuitive Surgical (ISRG) Gains on Strength in Robotics
by Zacks Equity Research
Higher adoption of Intuitive Surgical's (ISRG) robot-based da Vinci system and increasing procedure volumes are key catalysts at the moment.
Allscripts' iPro Anesthesia to be Administered by SingHealth
by Zacks Equity Research
Allscripts (MDRX) goes global, joining hands with Singapore-based hospital to implement iPro Anesthesia.
Here's Why You Should Buy Cooper Companies (COO) Stock Now
by Zacks Equity Research
Cooper Companies (COO) is set to gain from expanding product portfolio and increasing penetration in international markets.
Ecolab (ECL) Launches SMARTPOWER for Warewashing Efficiency
by Zacks Equity Research
Ecolab (ECL) rolls out SMARTPOWER program for efficient ware washing and reducing labor costs for restaurateurs.
Allscripts Acquires HealthGrid to Improve Patient Outcome
by Zacks Equity Research
Allscripts' (MDRX) HealthGrid buyout to drive FollowMyHealth platform.
Ligand Pharmaceuticals (LGND) Hits a 52-Week High, Can the Run Continue?
by Zacks Equity Research
Ligand Pharmaceuticals Incorporated is at a 52-week high, but can investors hope for more gains in the future? We take a look at the fundamentals for LGND for clues.
Cerner-VA Pact to Use EHR Platform for Better Veteran Service
by Zacks Equity Research
Department of Veterans Affairs adopts Cerner's (CERN) EHR system to serve the veteran community better.
Varian Medical (VAR) Merges With Brazil MOH to Fight Cancer
by Zacks Equity Research
Varian Medical (VAR) opts to spread radiotherapy accessibility in Latin America through Brazil MOH, other international ventures of the company hold promise.
Here's Why You Should Steer Clear of Cerner (CERN) for Now
by Zacks Equity Research
Cerner's (CERN) downbeat view for 2018 and soft Q1 results fail to cheer investors.
Here's Why You Should Sell DENTSPLY SIRONA (XRAY) Stock Now
by Zacks Equity Research
A rapidly changing healthcare environment in the United States, sluggish first quarter, declining margins and foreign exchange headwinds continue to hurt DENTSPLY SIRONA (XRAY).
Weakness Seen in Anika Therapeutics (ANIK) Estimates: Should You Stay Away?
by Zacks Equity Research
Anika Therapeutics (ANIK) has witnessed a significant price decline in the past four weeks, and has seen negative earnings estimate revisions for the current quarter and year.
Thermo Fisher (TMO) Gains on Latest Buyouts Despite Cost Woes
by Zacks Equity Research
Successive product launches and a marked progress in precision medicine initiatives boost Thermo Fisher's (TMO) performance.
Abaxis (ABAX) to be Acquired by Zoetis, Shares All-Time High
by Zacks Equity Research
Post takeover of Abaxis' (ABAX) point-of-care diagnostic instruments, Zoetis expects the consolidated company's veterinary diagnostics category to speed up growth over the animal health industry.
Cerner's (CERN) EHR Picked by Crisp Regional, Shares Up
by Zacks Equity Research
Crisp Regional chooses to implement Cerner's (CERN) EHR platform with a view to serve the community better.
Veeva Systems Launches Veeva Nitro, Boosts MedTech Analytics
by Zacks Equity Research
Veeva Systems' (VEEV) new commercial data warehouse establishes a solid data foundation, which will boost AI and analytics in the MedTech industry.
Can The Uptrend Continue for Genomic Health (GHDX)?
by Zacks Equity Research
Investors certainly have to be happy with Genomic Health, Inc. (GHDX) and its short term performance
Baxter (BAX) Gets FDA Nod for Spectrum IQ, Secures Infusions
by Zacks Equity Research
Baxter (BAX) streamlines EMR integration for patients through FDA's approval of Spectrum IQ.
Here's Why You Should Sell Fresenius Medical (FMS) Stock Now
by Zacks Equity Research
A rapidly changing healthcare environment in the United States, sluggish Q1 and competition in the niche markets are major headwinds for Fresenius Medical (FMS).
Here's Why You Should Invest in Varian Medical (VAR) Now
by Zacks Equity Research
Strong fundamentals and solid Q2 results make Varian Medical (VAR) a must buy.
Cerner EHR Range Picked by Indiana's FSSA for Patient Care
by Zacks Equity Research
Cerner (CERN) gains as Indiana FSSA chooses its flagship Cerner Millennium solutions to take better care of patients.
Here's Why You Should Invest in Intuitive Surgical Right Now
by Zacks Equity Research
Intuitive Surgical (ISRG) gains on solid Q1 results and strength in da Vinci platform.
Genomic Health (GHDX) Q1 Earnings Top Estimates, Margins Low
by Zacks Equity Research
Within Genomic Health's (GHDX) prostate cancer business, strengthened NCCN prostate cancer guidelines and additional new data increase private coverage for the Oncotype DX GPS test.
Why Is Genomic Health (GHDX) Up 1.6% Since Its Last Earnings Report?
by Zacks Equity Research
Genomic Health (GHDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Genomic Health (GHDX) Q4 Earnings & Revenues Miss Estimates
by Zacks Equity Research
Genomic Health's (GHDX) escalating operating expenses dent bottom line in Q4.